According to filings with the U.S. Securities and Exchange Commission, TECLens is raising up to $9,278,350.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Thomas Dunlap played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About TECLens
TECLens is leading the transformation of refractive vision care. The company has developed a novel, incisionless technology called quantitative corneal crosslinking or qCXLTM that can reshape your cornea without laser-ablation or invasive surgery. qCXLTM may be used to free presbyopic patients from the need for reading glasses, to prevent children from developing high myopia and to treat keratoconus. We believe our platform technology will revolutionize the existing standard of care for these eye care conditions. TECLens goal is to make our simple, cost-effective procedure the primary choice for patients seeking refractive correction, improving vision for millions of patients around the world. We are a young, emerging growth company with an entrepreneurial culture using a collaborative approach in all that we do. We are looking for talented and success-oriented people to join our team.

To learn more about TECLens, visit http://www.teclens.com/
Company Linkedin Page: https://www.linkedin.com/company/teclens/

Contact:
Thomas Dunlap, Chief Executive Officer
631-751-8670
https://www.linkedin.com/in/thomas-dunlap-0aa109/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.